Key takeaways
- • Medicare Advantage drug plans (MA-PD) cannot cover GLP-1s for weight loss — this is a federal statutory exclusion (SSA §1860D-2(e)(2)(A)), not a plan choice
- • T2D GLP-1s like Ozempic, Mounjaro, and Rybelsus may be covered when prescribed for diabetes with documentation — verify with your specific plan and current formulary
- • Wegovy and Zepbound may be covered by some MA-PD plans for their non-weight-loss FDA indications (cardiovascular risk reduction; obstructive sleep apnea) — verify with your specific plan and current formulary
- • Prior authorization is nearly universal for GLP-1s under MA-PD plans, and formulary inclusion varies significantly between carriers and plan years
- • The Treat and Reduce Obesity Act (TROA) would change this, but it has not been enacted as of 2026 — current law still excludes weight-loss drugs from Medicare
How Medicare Advantage (Part C with Part D / MA-PD) approaches GLP-1 coverage
MA-PD plans operate under the same Part D statutory framework as standalone PDPs. Under the Medicare Modernization Act of 2003 (SSA §1860D-2(e)(2)(A)), drugs used for weight loss are statutorily excluded — this binds every MA-PD plan regardless of carrier. When a GLP-1 carries a separate FDA-approved indication that is not weight loss, an MA-PD plan may elect to add it to formulary for that specific indication. Following the 2024 SELECT cardiovascular approval for Wegovy and the 2024 OSA approval for Zepbound, some MA-PD plans have added these drugs for those non-weight-loss indications — but coverage is plan-specific, frequently tiered as specialty, and almost always subject to prior authorization with documentation of the qualifying diagnosis. T2D GLP-1s (Ozempic, Mounjaro, Rybelsus) are commonly covered when prescribed for type 2 diabetes with appropriate clinical documentation. Verify every coverage assumption against your specific MA-PD plan's current-year formulary.
Statutory and structural notes
SSA §1860D-2(e)(2)(A), enacted via the Medicare Modernization Act of 2003, excludes "agents when used for anorexia, weight loss, or weight gain" from Part D — this binds all MA-PD plans. The Treat and Reduce Obesity Act (TROA) would amend this exclusion but has not been enacted as of 2026. The coverage exception applies only when a GLP-1 is prescribed for a separately FDA-approved non-weight-loss indication (e.g., Wegovy for cardiovascular risk reduction; Zepbound for moderate-to-severe OSA in adults with obesity).
Typically considered for coverage
The list below reflects general patterns observed across Medicare Advantage (Part C with Part D / MA-PD)plan documents. Coverage for any specific drug, dose, or indication must be confirmed against your own plan's current formulary and medical policy.
- Ozempic (semaglutide) when prescribed for type 2 diabetes with documented diagnosis — coverage and tier vary by plan formulary; verify with your specific plan and current formulary
- Mounjaro (tirzepatide) when prescribed for type 2 diabetes with documented diagnosis — coverage varies by plan; verify with your specific plan and current formulary
- Rybelsus (oral semaglutide) when prescribed for type 2 diabetes — coverage varies by plan; verify with your specific plan and current formulary
- Wegovy (semaglutide 2.4 mg) MAY be covered by MA-PD plans that have chosen to include it on formulary specifically for the FDA-approved cardiovascular risk reduction indication (post-SELECT, 2024) in patients with established CVD and overweight/obesity; verify with your specific plan and current formulary
- Zepbound (tirzepatide) MAY be covered by MA-PD plans that have chosen to include it on formulary specifically for the FDA-approved obstructive sleep apnea indication (2024) in adults with obesity; verify with your specific plan and current formulary
Typically excluded
- Any GLP-1 prescribed solely for weight loss or chronic weight management — statutorily excluded under SSA §1860D-2(e)(2)(A)
- Wegovy prescribed for weight management without the cardiovascular indication
- Zepbound prescribed for weight management without the OSA indication
- Saxenda (liraglutide) for weight loss
- Off-label use of T2D GLP-1s (Ozempic, Mounjaro, Rybelsus) for weight loss without a T2D diagnosis
- Compounded semaglutide or tirzepatide — generally not covered by Part D plans regardless of indication
Prior authorization
Prior authorization is commonly required for GLP-1 medications under Medicare Advantage (Part C with Part D / MA-PD) plans. Your prescriber typically submits a PA form with diagnosis codes, lab results (e.g., A1c for T2D, BMI for weight management), documented prior therapy attempts, and clinical justification.
Appeal strategy if denied
Request the written coverage determination, then file a Part D redetermination (Level 1) within 60 days. Submit prescriber documentation of the FDA-approved non-weight-loss indication (A1c/T2D labs; established CVD for Wegovy; sleep-study-confirmed OSA for Zepbound). Escalate to Independent Review Entity (Level 2), then ALJ hearing. Request expedited 72-hour review when urgent. Statutory weight-loss exclusion denials cannot be appealed on medical-necessity grounds.
GLP1Zoom is not an insurance company, broker, or health plan. We summarize general payer patterns from public plan documents and statute to help you ask the right questions. Always verify current coverage with your plan's member services. Full disclaimer.